Gerson JN, et al. - In a large cohort of transplantation-eligible patients 65 years of age or younger, survival was assessed retrospectively after autologous hematopoietic cell transplantation (AHCT) consolidation following induction chemotherapy in patients with mantle cell lymphoma (MCL). After propensity score–weighted (PSW) analysis, significantly improved progression-free survival (PFS), but not overall survival (OS), was evident in relation to AHCT consolidation after induction in this large cohort of younger, transplantation-eligible patients with MCL. PFS could be improved with AHCT consolidation in younger, fit patients.

Methods

• Participants in this retrospective analysis were transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015.
• Mainly, improved progression-free survival (PFS) with AHCT consolidation was the outcome of interest.
• Secondarily, they evaluated for improved overall survival (OS).
• They also carried out Cox multivariable regression analysis and propensity score–weighted (PSW) analysis.

Results

• Of 1,254 patients from 25 medical centers, for whom data were collected, 1,029 met inclusion criteria.
• The cohort was followed-up for a median duration of 76 months.
• Median PFS and OS were 62 and 139 months, respectively.
• In association with AHCT, improved PFS (75 v 44 months with vs without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05) were reported in unadjusted analysis.
• AHCT was found to be related to improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06), as seen in multivariable regression analysis.
• Even after PSW analysis, improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2) were seen in relation to AHCT.